nach oben

Clinical Oral Investigations

Erschienen in:

01.07.2014 | Original Article

TGF-βRI kinase activity mediates Emdogain-stimulated in vitro osteoclastogenesis

verfasst von: Reinhard Gruber, Gilles Roos, Jordi Caballé-Serrano, Rick Miron, Dieter D. Bosshardt, Anton Sculean

Erschienen in: Clinical Oral Investigations | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Emdogain, containing an extract of fetal porcine enamel matrix proteins, is a potent stimulator of in vitro osteoclastogenesis. The underlying molecular mechanisms are, however, unclear.

Material and methods

Here, we have addressed the role of transforming growth factor-beta receptor type 1 (TGF-βRI) kinase activity on osteoclastogenesis in murine bone marrow cultures.

Results

Inhibition of TGF-βRI kinase activity with SB431542 abolished the effect of Emdogain on osteoclastogenesis induced by receptor activator of nuclear factor kappa-B ligand or tumor necrosis factor-alpha. SB431542 also suppressed the Emdogain-mediated increase of OSCAR, a co-stimulatory protein, and dendritic cell-specific transmembrane protein and Atp6v0d2, the latter two being involved in cell fusion. Similar to transforming growth factor-beta1 (TGF-β), Emdogain could not compensate for the inhibition of IL-4 and IFNγ on osteoclast formation. When using the murine macrophage cell line RAW246.7, SB431542 and the smad-3 inhibitor SIS3 blocked Emdogain-stimulated expression of the transcription factor NFATc1.

Conclusions

Taken together, the data suggest that TGF-βRI kinase activity is necessary to mediate in vitro effects of Emdogain on osteoclastogenesis.

Clinical relevance

Based on these in vitro data, we can speculate that at least part of the clinical effects of Emdogain on osteoclastogenesis is mediated via TGF-β signaling.

Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342. doi:10.1038/nature01658 PubMedCrossRef

Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504–1508PubMedCrossRef

Kon T, Cho TJ, Aizawa T, Yamazaki M, Nooh N, Graves D, Gerstenfeld LC, Einhorn TA (2001) Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 16:1004–1014. doi:10.1359/jbmr.2001.16.6.1004 PubMedCrossRef

Braun T, Schett G (2012) Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep 10:101–108. doi:10.1007/s11914-012-0104-5 PubMedCrossRef

Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357PubMedCrossRef

Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428:758–763. doi:10.1038/nature02444 PubMedCrossRef

Kukita T, Wada N, Kukita A, Kakimoto T, Sandra F, Toh K, Nagata K, Iijima T, Horiuchi M, Matsusaki H, Hieshima K, Yoshie O, Nomiyama H (2004) RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med 200:941–946. doi:10.1084/jem.20040518 PubMedCentralPubMedCrossRef

Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y (2006) v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 12:1403–1409. doi:10.1038/nm1514 PubMedCrossRef

Bosshardt DD (2008) Biological mediators and periodontal regeneration: a review of enamel matrix proteins at the cellular and molecular levels. J Clin Periodontol 35:87–105. doi:10.1111/j.1600-051X.2008.01264.x PubMedCrossRef

10.

Grandin HM, Gemperli AC, Dard M (2012) Enamel matrix derivative: a review of cellular effects in vitro and a model of molecular arrangement and functioning. Tissue Eng Part B Rev 18:181–202. doi:10.1089/ten.TEB.2011.0365 PubMedCrossRef

11.

Sculean A, Alessandri R, Miron R, Salvi GE, Bosshardt DD (2011) Enamel matrix proteins and periodontal wound healing and regeneration. Clin Adv Periodontics 101–117. doi: 10.1111/j.1600-9657.2008.00559.x

12.

St George G, Darbar U, Thomas G (2006) Inflammatory external root resorption following surgical treatment for intra-bony defects: a report of two cases involving Emdogain and a review of the literature. J Clin Periodontol 33:449–454. doi:10.1111/j.1600-051X.2006.00926.x PubMedCrossRef

13.

Yagi Y, Suda N, Yamakoshi Y, Baba O, Moriyama K (2009) In vivo application of amelogenin suppresses root resorption. J Dent Res 88:176–181. doi:10.1177/0022034508329451 PubMedCrossRef

14.

Hamamoto Y, Kawasaki N, Jarnbring F, Hammarstrom L (2002) Effects and distribution of the enamel matrix derivative Emdogain in the periodontal tissues of rat molars transplanted to the abdominal wall. Dent Traumatol 18:12–23PubMedCrossRef

15.

Schjott M, Andreasen JO (2005) Emdogain does not prevent progressive root resorption after replantation of avulsed teeth: a clinical study. Dent Traumatol 21:46–50. doi:10.1111/j.1600-9657.2004.00295.x PubMedCrossRef

16.

Poi WR, Carvalho RM, Panzarini SR, Sonoda CK, Manfrin TM, Rodrigues Tda S (2007) Influence of enamel matrix derivative (Emdogain) and sodium fluoride on the healing process in delayed tooth replantation: histologic and histometric analysis in rats. Dent Traumatol 23:35–41. doi:10.1111/j.1600-9657.2006.00481.x PubMed

17.

Filippi A, Pohl Y, von Arx T (2006) Treatment of replacement resorption by intentional replantation, resection of the ankylosed sites, and Emdogain—results of a 6-year survey. Dent Traumatol 22:307–311. doi:10.1111/j.1600-9657.2005.00363.x PubMedCrossRef

18.

Fridstrom M, Schollin J, Crossner CG (2008) Evaluating Emdogain and healing of replanted teeth using an intra-individual experimental-control study design. Dent Traumatol 24:299–304. doi:10.1111/j.1600-9657.2008.00559.x PubMedCrossRef

19.

Itoh N, Kasai H, Ariyoshi W, Harada E, Yokota M, Nishihara T (2006) Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative. J Periodontal Res 41:273–279. doi:10.1111/j.1600-0765.2005.00868.x PubMedCrossRef

20.

Otsuka T, Kasai H, Yamaguchi K, Nishihara T (2005) Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures. J Dent 33:749–755. doi:10.1016/j.jdent.2005.02.006 PubMedCrossRef

21.

Kawase T, Okuda K, Yoshie H, Burns DM (2002) Anti-TGF-beta antibody blocks enamel matrix derivative-induced upregulation of p21WAF1/cip1 and prevents its inhibition of human oral epithelial cell proliferation. J Periodontal Res 37:255–262PubMedCrossRef

22.

Hama H, Azuma H, Seto H, Kido J, Nagata T (2008) Inhibitory effect of enamel matrix derivative on osteoblastic differentiation of rat calvaria cells in culture. J Periodontal Res 43:179–185. doi:10.1111/j.1600-0765.2007.01010.x PubMedCrossRef

23.

Wada Y, Yamamoto H, Nanbu S, Mizuno M, Tamura M (2008) The suppressive effect of enamel matrix derivative on osteocalcin gene expression of osteoblasts is neutralized by an antibody against TGF-beta. J Periodontol 79:341–347. doi:10.1902/jop.2008.070197 PubMedCrossRef

24.

Heng NH, N'Guessan PD, Kleber BM, Bernimoulin JP, Pischon N (2007) Enamel matrix derivative induces connective tissue growth factor expression in human osteoblastic cells. J Periodontol 78:2369–2379. doi:10.1902/jop.2007.070130 PubMedCrossRef

25.

Gruber R, Bosshardt DD, Richard JM, Gemperli AC, Buser D and Sculean A (2013) Enamel matrix derivative inhibits adipocyte differentiation of 3T3-L1 cells via activation of TGF-βRI kinase activity. PLoS One

26.

Sakoda K, Nakajima Y, Noguchi K (2012) Enamel matrix derivative induces production of vascular endothelial cell growth factor in human gingival fibroblasts. Eur J Oral Sci 120:513–519. doi:10.1111/j.1600-0722.2012.00999.x PubMedCrossRef

27.

Fox SW, Fuller K, Bayley KE, Lean JM, Chambers TJ (2000) TGF-beta 1 and IFN-gamma direct macrophage activation by TNF-alpha to osteoclastic or cytocidal phenotype. J Immunol 165:4957–4963PubMedCrossRef

28.

Fox SW, Evans KE, Lovibond AC (2008) Transforming growth factor-beta enables NFATc1 expression during osteoclastogenesis. Biochem Biophys Res Commun 366:123–128. doi:10.1016/j.bbrc.2007.11.120 PubMedCentralPubMedCrossRef

29.

Miyazono K, Hellman U, Wernstedt C, Heldin CH (1988) Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem 263:6407–6415PubMed

30.

Nagano T, Iwata T, Ogata Y, Tanabe T, Gomi K, Fukae M, Arai T, Oida S (2004) Effect of heat treatment on bioactivities of enamel matrix derivatives in human periodontal ligament (HPDL) cells. J Periodontal Res 39:249–256. doi:10.1111/j.1600-0765.2004.00733.x PubMedCrossRef

31.

Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, Kim JH, Kobayashi T, Odgren PR, Nakano H, Yeh WC, Lee SK, Lorenzo JA, Choi Y (2005) Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 202:589–595. doi:10.1084/jem.20050978 PubMedCentralPubMedCrossRef

32.

Cicek M, Vrabel A, Sturchio C, Pederson L, Hawse JR, Subramaniam M, Spelsberg TC, Oursler MJ (2011) TGF-beta inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways. PLoS One 6:e17522. doi:10.1371/journal.pone.0017522 PubMedCentralPubMedCrossRef

33.

Yasui T, Kadono Y, Nakamura M, Oshima Y, Matsumoto T, Masuda H, Hirose J, Omata Y, Yasuda H, Imamura T, Nakamura K, Tanaka S (2011) Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J Bone Miner Res 26:1447–1456. doi:10.1002/jbmr.357 PubMedCrossRef

34.

Lou Z, Yang Y, Ren T, Tang S, Peng X, Lu Q, Sun Y, Guo W (2013) Smad3 is the key to transforming growth factor-beta1-induced osteoclast differentiation in giant cell tumor of bone. Med Oncol 30:606. doi:10.1007/s12032-013-0606-8 PubMedCrossRef

35.

Kawase T, Okuda K, Momose M, Kato Y, Yoshie H, Burns DM (2001) Enamel matrix derivative (EMDOGAIN) rapidly stimulates phosphorylation of the MAP kinase family and nuclear accumulation of smad2 in both oral epithelial and fibroblastic human cells. J Periodontal Res 36:367–376PubMedCrossRef

36.

Saito K, Konishi I, Nishiguchi M, Hoshino T, Fujiwara T (2008) Amelogenin binds to both heparan sulfate and bone morphogenetic protein 2 and pharmacologically suppresses the effect of noggin. Bone 43:371–376. doi:10.1016/j.bone.2008.03.029 PubMedCrossRef

37.

Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT (2001) Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 16:1787–1794. doi:10.1359/jbmr.2001.16.10.1787 PubMedCrossRef

38.

Thirunavukkarasu K, Miles RR, Halladay DL, Yang X, Galvin RJ, Chandrasekhar S, Martin TJ, Onyia JE (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem 276:36241–36250. doi:10.1074/jbc.M104319200 PubMedCrossRef

39.

Edwards JR, Nyman JS, Lwin ST, Moore MM, Esparza J, O'Quinn EC, Hart AJ, Biswas S, Patil CA, Lonning S, Mahadevan-Jansen A, Mundy GR (2010) Inhibition of TGF-beta signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res 25:2419–2426. doi:10.1002/jbmr.139 PubMedCrossRef

40.

Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T (2009) Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 4:e5275. doi:10.1371/journal.pone.0005275 PubMedCentralPubMedCrossRef

41.

Brett PM, Parkar M, Olsen I, Tonetti M (2002) Expression profiling of periodontal ligament cells stimulated with enamel matrix proteins in vitro: a model for tissue regeneration. J Dent Res 81:776–783PubMedCrossRef

42.

Elias JA, Zheng T, Whiting NL, Trow TK, Merrill WW, Zitnik R, Ray P, Alderman EM (1994) IL-1 and transforming growth factor-beta regulation of fibroblast-derived IL-11. J Immunol 152:2421–2429PubMed

43.

Takayanagi K, Osawa G, Nakaya H, Cochran DL, Kamoi K, Oates TW (2006) Effects of enamel matrix derivative on bone-related mRNA expression in human periodontal ligament cells in vitro. J Periodontol 77:891–898. doi:10.1902/jop.2006.050244 PubMedCrossRef

44.

Hatakeyama J, Sreenath T, Hatakeyama Y, Thyagarajan T, Shum L, Gibson CW, Wright JT, Kulkarni AB (2003) The receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenic pathway is elevated in amelogenin-null mice. J Biol Chem 278:35743–35748. doi:10.1074/jbc.M306284200 PubMedCrossRef

45.

Tachi K, Takami M, Sato H, Mochizuki A, Zhao B, Miyamoto Y, Tsukasaki H, Inoue T, Shintani S, Koike T, Honda Y, Suzuki O, Baba K, Kamijo R (2011) Enhancement of bone morphogenetic protein-2-induced ectopic bone formation by transforming growth factor-beta1. Tissue Eng Part A 17:597–606. doi:10.1089/ten.TEA.2010.0094 PubMedCrossRef

Titel: TGF-βRI kinase activity mediates Emdogain-stimulated in vitro osteoclastogenesis
verfasst von: Reinhard Gruber
Gilles Roos
Jordi Caballé-Serrano
Rick Miron
Dieter D. Bosshardt
Anton Sculean
Publikationsdatum: 01.07.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Oral Investigations / Ausgabe 6/2014
Print ISSN: 1432-6981
Elektronische ISSN: 1436-3771
DOI: https://doi.org/10.1007/s00784-013-1129-6

Bestellen Sie unseren kostenlosen Newsletter Update Zahnmedizin und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

TGF-βRI kinase activity mediates Emdogain-stimulated in vitro osteoclastogenesis